OBJECTIVE: To investigate whether hormone therapy (HT) and obesity are associated with endometrial cancer risk among postmenopausal women in the California Teachers Study cohort. METHODS: Of 28,418 postmenopausal women, 395 developed type 1 endometrial cancer between 1995 and 2006. Multivariate Cox regression was performed to estimate relative risks (RR), stratified by HT use (never used, ever estrogen alone (ET) or exclusively estrogen-plus-progestin (EPT)). RESULTS: Among women who never used HT, overall and abdominal adiposity were associated with increased risk; when evaluated simultaneously, abdominal adiposity was more strongly associated (RR 2.2, 95% confidence interval (CI): 1.1-4.5 for waist >or=35 vs. <35 inches). Among women who ever used ET, risk was increased in women with BMI >or= 25 kg/m(2) (RR 1.6, 95% CI: 1.1-2.3 vs. <25 kg/m(2)). Neither overall nor abdominal obesity was associated with risk in women who exclusively used EPT (p-interaction <0.001 for BMI by HT use). CONCLUSIONS: Among women who never used HT, risk was strongly positively related to obesity and may have been influenced more by abdominal than by overall adiposity; however, due to small numbers, this latter finding requires replication. Among women who ever used ET, being overweight at baseline predicted higher risk, whereas use of EPT mitigated any effects of obesity.
OBJECTIVE: To investigate whether hormone therapy (HT) and obesity are associated with endometrial cancer risk among postmenopausal women in the California Teachers Study cohort. METHODS: Of 28,418 postmenopausal women, 395 developed type 1 endometrial cancer between 1995 and 2006. Multivariate Cox regression was performed to estimate relative risks (RR), stratified by HT use (never used, ever estrogen alone (ET) or exclusively estrogen-plus-progestin (EPT)). RESULTS: Among women who never used HT, overall and abdominal adiposity were associated with increased risk; when evaluated simultaneously, abdominal adiposity was more strongly associated (RR 2.2, 95% confidence interval (CI): 1.1-4.5 for waist >or=35 vs. <35 inches). Among women who ever used ET, risk was increased in women with BMI >or= 25 kg/m(2) (RR 1.6, 95% CI: 1.1-2.3 vs. <25 kg/m(2)). Neither overall nor abdominal obesity was associated with risk in women who exclusively used EPT (p-interaction <0.001 for BMI by HT use). CONCLUSIONS: Among women who never used HT, risk was strongly positively related to obesity and may have been influenced more by abdominal than by overall adiposity; however, due to small numbers, this latter finding requires replication. Among women who ever used ET, being overweight at baseline predicted higher risk, whereas use of EPT mitigated any effects of obesity.
Authors: Shih-Chen Chang; James V Lacey; Louise A Brinton; Patricia Hartge; Kenneth Adams; Traci Mouw; Leslie Carroll; Albert Hollenbeck; Arthur Schatzkin; Michael F Leitzmann Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-04 Impact factor: 4.254
Authors: Marjorie L McCullough; Alpa V Patel; Roshni Patel; Carmen Rodriguez; Heather Spencer Feigelson; Elisa V Bandera; Ted Gansler; Michael J Thun; Eugenia E Calle Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-01-09 Impact factor: 4.254
Authors: Christine Friedenreich; Anne Cust; Petra H Lahmann; Karen Steindorf; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon; Sylvie Mesrine; Jakob Linseisen; Sabine Rohrmann; Heiner Boeing; Tobias Pischon; Anne Tjønneland; Jytte Halkjaer; Kim Overvad; Michelle Mendez; M L Redondo; Carmen Martinez Garcia; Nerea Larrañaga; María-José Tormo; Aurelio Barricarte Gurrea; Sheila Bingham; Kay-Tee Khaw; Naomi Allen; Tim Key; Antonia Trichopoulou; Effie Vasilopoulou; Dimitrios Trichopoulos; Valeria Pala; Domenico Palli; Rosario Tumino; Amalia Mattiello; Paolo Vineis; H Bas Bueno-de-Mesquita; Petra H M Peeters; Göran Berglund; Jonas Manjer; Eva Lundin; Annekatrin Lukanova; Nadia Slimani; Mazda Jenab; Rudolf Kaaks; Elio Riboli Journal: Cancer Causes Control Date: 2007-02-12 Impact factor: 2.506
Authors: Marcelle M Dougan; Susan E Hankinson; Immaculata De Vivo; Shelley S Tworoger; Robert J Glynn; Karin B Michels Journal: Int J Cancer Date: 2015-02-05 Impact factor: 7.396
Authors: Britton Trabert; Nicolas Wentzensen; Hannah P Yang; Mark E Sherman; Albert R Hollenbeck; Yikyung Park; Louise A Brinton Journal: Int J Cancer Date: 2012-08-30 Impact factor: 7.396
Authors: Veronica Wendy Setiawan; Malcolm C Pike; Stalo Karageorgi; Sandra L Deming; Kristin Anderson; Leslie Bernstein; Louise A Brinton; Hui Cai; James R Cerhan; Wendy Cozen; Chu Chen; Jennifer Doherty; Jo L Freudenheim; Marc T Goodman; Susan E Hankinson; James V Lacey; Xiaolin Liang; Jolanta Lissowska; Lingeng Lu; Galina Lurie; Thomas Mack; Rayna K Matsuno; Susan McCann; Kirsten B Moysich; Sara H Olson; Radhai Rastogi; Timothy R Rebbeck; Harvey Risch; Kim Robien; Catherine Schairer; Xiao-Ou Shu; Amanda B Spurdle; Brian L Strom; Pamela J Thompson; Giske Ursin; Penelope M Webb; Noel S Weiss; Nicolas Wentzensen; Yong-Bing Xiang; Hannah P Yang; Herbert Yu; Pamela L Horn-Ross; Immaculata De Vivo Journal: Am J Epidemiol Date: 2012-07-23 Impact factor: 4.897
Authors: Stephanie Whisnant Cash; Huiyan Ma; Pamela L Horn-Ross; Peggy Reynolds; Alison J Canchola; Jane Sullivan-Halley; Shirley A A Beresford; Marian L Neuhouser; Thomas L Vaughan; Patrick J Heagerty; Leslie Bernstein Journal: Cancer Epidemiol Date: 2012-10-30 Impact factor: 2.984
Authors: Hannah P Yang; Nicolas Wentzensen; Britton Trabert; Gretchen L Gierach; Ashley S Felix; Marc J Gunter; Albert Hollenbeck; Yikyung Park; Mark E Sherman; Louise A Brinton Journal: Am J Epidemiol Date: 2012-11-21 Impact factor: 4.897
Authors: Todd R Sponholtz; Julie R Palmer; Lynn Rosenberg; Elizabeth E Hatch; Lucile L Adams-Campbell; Lauren A Wise Journal: Am J Epidemiol Date: 2016-01-27 Impact factor: 4.897
Authors: L Dal Maso; A Tavani; A Zucchetto; M Montella; M Ferraroni; E Negri; J Polesel; A Decarli; R Talamini; C La Vecchia; S Franceschi Journal: Br J Cancer Date: 2011-03-08 Impact factor: 7.640